- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02189707
Effects of Probiotic Supplementation on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Constipation.
Effects of 4-week Bifidobacterium-lactis HN019 Supplementation on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebo-controlled Dose-ranging Trial
Study Overview
Status
Conditions
Detailed Description
Constipation is a commonly diagnosed gastrointestinal disorder with an estimated prevalence in the general population of 12-19%, which results in lower quality of life and significant healthcare costs to the individual. Almost 9 in 10 physician visits for constipation result in a laxative prescription. Additionally, consumers in the USA and in the United Kingdom spend almost 1 billion dollars annually for over-the-counter laxatives. Chronic constipation is diagnosed almost solely on patient symptoms, which generally includes unsatisfactory defecation due to infrequent stools, difficult stool passage, or both. The cause of chronic constipation is unknown and likely multifactorial with physiological changes, psychological factors, and lifestyle influences identified as possible culprits. Consequently, identification of effective constipation treatments remains a challenge.
The initial management of constipation symptoms is focused on evaluating lifestyle and diet variables as possible culprits. If lifestyle modifications are unsuccessful in alleviating constipation, various medications may be prescribed. In fact, about 50% of adults with constipation are not completely satisfied with available treatments. Consequently, there is a clear need for alternative constipation treatments that are safe, effective, and cost-effective.
Probiotics are live micro-organisms that result in a health benefit for the host when administered in adequate dosages. In recent years, probiotics have been commonly used to alleviate symptoms in a variety of gastrointestinal disorders. It is hypothesized that probiotics help to maintain gut lumen homeostasis by hindering growth of luminal pathogens and restoring the normal flora of the gut. As such, the use of probiotics for the relief of constipation symptoms is very promising. Numerous studies have been published addressing the utility of probiotics for gastrointestinal health including constipation. However, since probiotic efficacy is largely strain-specific, each specific strain must be individually tested in clinical trials.
Given the promising clinical results of probiotics on gastrointestinal health to date, the objective of this clinical trial is to evaluate the safety and effectiveness of 4-week Bifidobacterium lactis HN019 supplementation, in a dose-ranging fashion, on Colonic Transit Time (CTT) and gastrointestinal symptoms in adults with constipation.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Gières, France, 38610
- Eurofins Optimed Clinical research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Age 18 to 70 years
- 2.Body mass index between 18.5 and 34.9 kg/m2
3. Meets the Rome III criteria for functional constipation as follows: (Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis):
Must meet 2 or more of the following criteria:
- Straining during at least 25% of defecations
- Lumpy or hard stools in at least 25% of defecations
- Sensation of incomplete evacuation for at least 25% of defecations
- Sensation of anorectal obstruction/blockage for at least 25% of defecations+ Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor)
- Fewer than three defecations per week
- Loose stools are rarely present without the use of laxatives
- Insufficient criteria for irritable bowel syndrome
Exclusion Criteria:
- 1.Major gastrointestinal complication (e.g. Crohn's disease, ulcer)
- 2. Prior abdominal surgery that, in the opinion of the investigator, may present a risk for the participant or confound study results
- 3. Clinically significant underlying systemic illness that may preclude the participant's ability to complete the trial or that may confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness)
- 4. Daily consumption of probiotics, prebiotics, fermented milk, and/or yogurt within 2 weeks of screening and throughout the trial other than the provided study products
- 5. Laxative use within 48 hours of screening (rescue medication allowed for intolerable symptoms during study)
- 6. Regular use of any drug or dietary supplement known to cause constipation (e.g. iron, opioids, sucralfate, misoprostol, 5-Hydroxytryptamine#-antagonists, antacids with magnesium, calcium or aluminum, antidiarrheal medication, anticholinergic agents, calcium supplements, calcium channel blockers, tricyclic antidepressants or nonsteroidal antiinflammatory drugs), within 1 month before screening.
- 7. Anticipated major dietary or exercise changes during the study
- 8. Systemic steroid use, within 1 month before screening.
- 9. Eating disorder
- 10. Contraindication to dairy products (e.g., intolerance to lactose or any substance in the study product)
- 11. History of alcohol, drug, or medication abuse
- 12. Pregnant or lactating female, or pregnancy planned during study period.
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Probiotic Bifidobacterium 1x1010 cfu
One capsule of study product, mixed with provided yogurt, will be consumed once a day.
|
Participants who pass the initial screening will enter a 2-week placebo-only run-in period.
Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
Other Names:
|
Experimental: Probiotic Bifidobacterium 1x109 cfu
One capsule of study product, mixed with provided yogurt, will be consumed once a day.
|
Participants who pass the initial screening will enter a 2-week placebo-only run-in period.
Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
One capsule of study product, mixed with provided yogurt, will be consumed once a day.
Other Names:
|
Placebo Comparator: Placebo powder in capsules
One capsule of study product, mixed with provided yogurt, will be consumed once a day.
|
Participants will consume placebo capsules only during the 2-week run-in period.
After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Colonic transit time
Time Frame: The primary outcome of Colonic Transit Time will be evaluated with abdominal x-rays on days 0 and 28
|
The primary outcome of Colonic Transit Time will be evaluated with abdominal x-rays on days 0 and 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient (syn. participant) assessment of constipation symptoms (PAC-SYM)
Time Frame: At days 0 and 28
|
At days 0 and 28
|
Patient Assessment of Constipation Quality of Life (PAC-QoL)
Time Frame: At days 0 and 28
|
At days 0 and 28
|
Bowel Function Index
Time Frame: At days 0 and 28
|
At days 0 and 28
|
Adequate Relief of constipation (yes/no)
Time Frame: At days 0 and 28
|
At days 0 and 28
|
Bowel movement frequency stools per week)
Time Frame: Participants will record the number of defecations per day in a daily diary during the 2-week run-in period and each day during the 4-week supplementation period
|
Participants will record the number of defecations per day in a daily diary during the 2-week run-in period and each day during the 4-week supplementation period
|
Stool consistency (Bristol Stool Scale)
Time Frame: Participants will record stool consistency during the 2-week run-in period and each day during the 4-week supplementation period.
|
Participants will record stool consistency during the 2-week run-in period and each day during the 4-week supplementation period.
|
Degree of Straining (1-5 scale)
Time Frame: Participants will record degree of straining during the 2-week run-in period and each day during the 4-week supplementation period.
|
Participants will record degree of straining during the 2-week run-in period and each day during the 4-week supplementation period.
|
Participant assessment of bowel emptying (yes/no)
Time Frame: Participants will record sensation of complete bowel emptying during the 2-week run-in period and each day during the 4-week supplementation period.
|
Participants will record sensation of complete bowel emptying during the 2-week run-in period and each day during the 4-week supplementation period.
|
Abdominal discomfort/bloating (1-5 scale)
Time Frame: Participants will record severity of abdominal discomfort and bloating during the 2-week run-in period and each day during the 4-week supplementation period.
|
Participants will record severity of abdominal discomfort and bloating during the 2-week run-in period and each day during the 4-week supplementation period.
|
Overall product satisfaction (1-5 scale)
Time Frame: At the end of the supplementation period (D28)
|
At the end of the supplementation period (D28)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Bifido transit 3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
ProgenaBiomeRecruitingConstipation | Constipation - Functional | Constipation Chronic Idiopathic | Constipation (Excl Faecal Impaction)United States
-
Pamukkale UniversityRecruiting
-
Shanghai University of Traditional Chinese MedicineLonghua Hospital; Shanghai Municipal Hospital of Traditional Chinese MedicineRecruiting
-
Universidade Nova de LisboaCINTESIS - Center for Health Technology and Services ResearchRecruiting
Clinical Trials on Probiotic Bifidobacterium 1x1010 cfu
-
University of CopenhagenOdense University Hospital; University of Bergen; Chr Hansen; Statens Serum Institut and other collaboratorsTerminatedRespiratory Tract Infections | Allergy | Gastrointestinal Infections | Days Absent From Day CareDenmark
-
University of CopenhagenOdense University Hospital; University of Bergen; Chr Hansen; Statens Serum Institut and other collaboratorsCompletedRespiratory Tract Infections | Allergy | Gastrointestinal Infections | Days Absent From DaycareDenmark
-
DaniscoCompleted
-
Renew Life Formulas IncSprim Advanced Life SciencesUnknown
-
Nordic Biotic Sp. z o.o.Medical University of LublinCompletedIrritable Bowel SyndromePoland
-
Georgetown UniversityCargillCompletedDigestive Irregularity | Digestive Discomfort | History of Straining During Bowel Movements | History of Hard or Lumpy StoolsUnited States
-
Azienda Ospedaliero Universitaria Maggiore della...Completed
-
Universidade Federal do Rio de JaneiroRio de Janeiro State Research Supporting Foundation (FAPERJ)Completed
-
University of FloridaLallemand Human NutritionCompleted